Company / Interest Expense
Apellis Pharmaceuticals, Inc. Interest Expense History
FY2020-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$5.7M
FY2022
5-year range
$5.7M / $12.1M
FY2020-FY2022
Trend
-52.6%
vs FY2021
Sector context
#33 of 44
Health Care
What the data says
Apellis Pharmaceuticals, Inc.'s interest expense of $6M is lower than 75% of companies in the Health Care sector (FY2022). Increased from $4M to $6M over the past 2 years.
Based on SEC 10-K filings.
$6M in FY2022.
Increased from $4M to $6M over the past 2 years.
Health Care sector context is included.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 25% in Health CareTop 25% of 44This company $5.7M Sector average $291.0M
▼
-98.0% below sector average
Key checks
Key Insights
- In FY2022, interest expense decreased 52.6% year-over-year.
- Ranks #33 out of 44 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $5.7M | -52.6% |
| FY2021 | $12.1M | +236.3% |
| FY2020 | $3.6M | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2017 | - | - |
| FY2016 | - | - |
As of FY2022 · SEC 10-K · Updated Feb 28, 2026